Opinion|Videos|August 28, 2024
Examining Trial Data on Omaveloxolone Efficacy
A physician examines clinical trial results that impact their approach to treating patients with Friedreich ataxia.
Advertisement
Episodes in this series
- In 2023, a propensity matched comparison of MOXIe extension patients to an untreated cohort found a significant slowing of disease progression per mFARS of 3.0 points compared to 6.6 points, respectively. Are these results clinically meaningful for patients and how does this relate to your everyday clinical practice?
Advertisement
Related Content
Advertisement
Advertisement
Trending on AJMC
1
US Employer Health Care Costs Projected to Rise 9.5% in 2027
2
Daraxonrasib Clears FDA as First RAS-Targeted Pancreatic Cancer Drug
3
FDA Clears First Single-Biomarker Blood Test for Alzheimer
4
New York Experts Push for Coordinated Obesity Care Teams
5